Literature DB >> 30042206

Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition.

Douglas B Johnson1, Kimberly B Dahlman2.   

Abstract

Mutations in BRAF outside of the 600 codons (BRAF non- V600) occur across cancer types, including in 3% to 5% of melanomas. The optimal treatment strategies are not clear but based on preclinical studies could include MEK inhibitors. Combining BRAF and MEK inhibitors in this population may provide additional benefit.See related article by Dankner et al., p. 6483. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30042206      PMCID： PMC6295213          DOI： 10.1158/1078-0432.CCR-18-1795

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.

Authors:  Matthew Dankner; Mathieu Lajoie; Dan Moldoveanu; Tan-Trieu Nguyen; Paul Savage; Shivshankari Rajkumar; Xiu Huang; Maria Lvova; Alexei Protopopov; Dana Vuzman; David Hogg; Morag Park; Marie-Christine Guiot; Kevin Petrecca; Catalin Mihalcioiu; Ian R Watson; Peter M Siegel; April A N Rose
Journal:  Clin Cancer Res       Date:  2018-06-14       Impact factor: 12.531

2.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Authors:  Kevin B Kim; Richard Kefford; Anna C Pavlick; Jeffrey R Infante; Antoni Ribas; Jeffrey A Sosman; Leslie A Fecher; Michael Millward; Grant A McArthur; Patrick Hwu; Rene Gonzalez; Patrick A Ott; Georgina V Long; Olivia S Gardner; Daniele Ouellet; Yanmei Xu; Douglas J DeMarini; Ngocdiep T Le; Kiran Patel; Karl D Lewis
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

3.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

4.  BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

Authors:  Kimberly Brown Dahlman; Junfeng Xia; Katherine Hutchinson; Charles Ng; Donald Hucks; Peilin Jia; Mohammad Atefi; Zengliu Su; Suzanne Branch; Pamela L Lyle; Donna J Hicks; Viviana Bozon; John A Glaspy; Neal Rosen; David B Solit; James L Netterville; Cindy L Vnencak-Jones; Jeffrey A Sosman; Antoni Ribas; Zhongming Zhao; William Pao
Journal:  Cancer Discov       Date:  2012-07-13       Impact factor: 39.397

5.  Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

Authors:  Zhan Yao; Rona Yaeger; Vanessa S Rodrik-Outmezguine; Anthony Tao; Neilawattie M Torres; Matthew T Chang; Matthias Drosten; Huiyong Zhao; Fabiola Cecchi; Todd Hembrough; Judith Michels; Hervé Baumert; Linde Miles; Naomi M Campbell; Elisa de Stanchina; David B Solit; Mariano Barbacid; Barry S Taylor; Neal Rosen
Journal:  Nature       Date:  2017-08-02       Impact factor: 49.962
  5 in total
  4 in total

1.  Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.

Authors:  Luz D Gutiérrez-Castañeda; Mauricio Gamboa; John A Nova; Leonardo Pulido; Jose D Tovar-Parra
Journal:  Biomed Res Int       Date:  2020-07-22       Impact factor: 3.411

2.  MEK inhibitors in non-V600 BRAF mutations and fusions.

Authors:  Douglas B Johnson; Caroline A Nebhan; Marcus S Noel
Journal:  Oncotarget       Date:  2020-11-03

Review 3.  BRAF Gene and Melanoma: Back to the Future.

Authors:  Margaret Ottaviano; Emilio Francesco Giunta; Marianna Tortora; Marcello Curvietto; Laura Attademo; Davide Bosso; Cinzia Cardalesi; Mario Rosanova; Pietro De Placido; Erica Pietroluongo; Vittorio Riccio; Brigitta Mucci; Sara Parola; Maria Grazia Vitale; Giovannella Palmieri; Bruno Daniele; Ester Simeone
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

4.  Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.

Authors:  Jeff Owsley; Matthew K Stein; Jason Porter; Gino K In; Mohamed Salem; Steven O'Day; Andrew Elliott; Kelsey Poorman; Geoffrey Gibney; Ari VanderWalde
Journal:  Exp Biol Med (Maywood)       Date:  2020-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.